Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed 10 enrolled Arch Oncology

Non-randomizedSequentialOpen-labelTreatment

Summary

Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).

Timeline

Start: 2020-11-30
Primary completion: 2022-08-05
Completion: 2022-11-14

Publications

Andrejeva G, Capoccia BJ, Hiebsch RR, Donio MJ, Darwech IM, Puro RJ, Pereira DS. Novel SIRPalpha Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J Immunol. 2021 Feb 15;206(4):712-721. doi: 10.4049/jimmunol.2001019. Epub 2021 Jan 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AO-176	Monoclonal antibody	—	—
Background	Bortezomib	Small molecule	—	—
Background	Dexamethasone	Small molecule	—	—

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications